<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091177</url>
  </required_header>
  <id_info>
    <org_study_id>2021JiNan</org_study_id>
    <nct_id>NCT05091177</nct_id>
  </id_info>
  <brief_title>Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis</brief_title>
  <official_title>Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XiaoYong Liu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Jinan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ocular myasthenia gravis (OMG) is an autoimmune neuromuscular disease mediated by pathogenic&#xD;
      autoantibodies. Its etiology and pathogenesis are not completely clear. The occurrence and&#xD;
      development of OMG are the result of the joint participation of genetic factors,&#xD;
      environmental factors and immune factors. The role of infectious factors in the pathogenesis&#xD;
      of autoimmune diseases is a hot topic in the international discussion.By analyzing the&#xD;
      difference in the positive rate and titer of CMV antibodies between ocular myasthenia gravis&#xD;
      and healthy people. By analyzing the correlation between the positive rate and titer of CMV&#xD;
      antibodies and ocular myasthenia gravis clinical manifestations, acetylcholine receptor&#xD;
      antibodies, ESR, hypersensitive C-reactive protein, complement C3, complement C4 and thymus&#xD;
      status.To investigate the correlation between cytomegalovirus and ocular myasthenia gravis.&#xD;
      It can provide new insights for further studies on the etiology and possible pathogenesis of&#xD;
      ocular myasthenia gravis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 75 patients and 40 healthy volunteers are collected who are diagnosed with ocular&#xD;
      myasthenia gravis in the First Affiliated Hospital of Jinan University from January 2019 to&#xD;
      January 2022 . All subjects undergo eye examination and cytomegalovirus antibody detection.&#xD;
      OMG patients undergo the following examinations: serum acetylcholine receptor antibody,&#xD;
      erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low&#xD;
      frequency repetitive nerve stimulation (orbicularis oculi, levator palpebrae superioris,&#xD;
      frontalis muscle), thyroid function and color ultrasound. The difference of lgG positive rate&#xD;
      ,lgM positive rate of CMV and antibody titers of lgG and lgM are analyzed between the two&#xD;
      groups, and the relationship between CMV antibody and OMG clinical manifestations,&#xD;
      acetylcholine receptor antibody, laboratory indicators and thymus status are analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>CMV lgG, lgM positive rate</measure>
    <time_frame>1year</time_frame>
    <description>CMV-lgG titer â‰¥14IU/ mL is positive, 12-14 IU/ mL is critical, and 0-12 IU/ mL is negative. CMV-lgM titer &gt; 22U/ mL is positive, 18-22U/mL is critical, and 0-18U/mL is negative.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CMV lgG, lgM antibody titer</measure>
    <time_frame>1year</time_frame>
    <description>Concentrations of cytomegalovirus lgG and lgM antibodies is collected for analysis.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Ocular Myasthenia Gravis</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>the patience group</arm_group_label>
    <description>underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and color ultrasound.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the normal group</arm_group_label>
    <description>underwent the following examinations: serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test, chest CT, low frequency repetitive nerve stimulation (orbicularis oculi muscle, levator palpebrae muscle, frontalis muscle), thyroid function and ultrasound.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation</intervention_name>
    <description>Use relevant instruments for inspection</description>
    <arm_group_label>the normal group</arm_group_label>
    <arm_group_label>the patience group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 75 patients and 40 healthy volunteers are collected who are diagnosed with&#xD;
        ocular myasthenia gravis in the First Affiliated Hospital of Jinan University from January&#xD;
        2019 to January 2022&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        the patience group Inclusion criteria:&#xD;
&#xD;
          -  Clinical manifestations: fluctuating eye muscle weakness;&#xD;
&#xD;
          -  Positive ice test, fatigue test, rest and sleep test;&#xD;
&#xD;
          -  Positive neostigmine test;&#xD;
&#xD;
          -  Serum acetylcholine receptor antibody and other antibodies are positive;&#xD;
&#xD;
          -  Repeated electrical nerve stimulation test attenuation is positive;&#xD;
&#xD;
          -  Meeting the above diagnostic criteria of the first, or any of the other 4, at the same&#xD;
             time excluding other diseases caused by eye palsy can be clear diagnosis.&#xD;
&#xD;
        the patience group exclusion criteria:&#xD;
&#xD;
          -  General myasthenia gravis;&#xD;
&#xD;
          -  History of other eye diseases&#xD;
&#xD;
          -  With other autoimmune diseases or other inflammatory diseases;&#xD;
&#xD;
          -  Patients with diabetes, hypertension, coronary heart disease and other chronic medical&#xD;
             history or cancer diseases;&#xD;
&#xD;
          -  Hepatitis B virus, hepatitis C virus, HIV, syphilis positive patients;&#xD;
&#xD;
          -  immunosuppressive drugs (such as glucocorticoid, azathioprine and cyclosporine A),&#xD;
             gamma globulin for intravenous injection, plasmapheresis, etc., within 3 months before&#xD;
             treatment;&#xD;
&#xD;
          -  Previous thymic resection or thymus radiation therapy;&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
        the control group Inclusion criteria:&#xD;
&#xD;
          -  No obvious abnormality was found in the recent physical examination results;&#xD;
&#xD;
          -  No history of autoimmune diseases;&#xD;
&#xD;
          -  Have not received antiviral therapy or immunotherapy within 3 months;&#xD;
&#xD;
          -  No history of other eye diseases or systemic diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Jinan University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qing Zhou</last_name>
      <phone>18928903759</phone>
      <email>kerryzh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Jinan University</investigator_affiliation>
    <investigator_full_name>XiaoYong Liu</investigator_full_name>
    <investigator_title>Deputy chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Myasthenia Gravis</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcholine</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

